Executives from major PBMs will testify before the House Oversight Committee on the impact of PBMs on prescription drug costs. Bipartisan pressure is mounting for reforms due to concerns over pricing practices. The hearing aims to address anticompetitive tactics and potential reforms to lower drug prices.